Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) and Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ritter Pharmaceuticals Inc.	N/A	0.00	19.41M	-3.08	0.00
Opiant Pharmaceuticals Inc.	13.98M	3.34	21.20M	-3.91	0.00

In table 1 we can see Ritter Pharmaceuticals Inc. and Opiant Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both companies.

	Net Margins	Return on Equity	Return on Assets
Ritter Pharmaceuticals Inc.	0.00%	-135%	-86.8%
Opiant Pharmaceuticals Inc.	-151.65%	0%	0%

Risk and Volatility

Ritter Pharmaceuticals Inc.’s 1.45 beta indicates that its volatility is 45.00% more volatile than that of S&P 500. Opiant Pharmaceuticals Inc.’s 14.00% more volatile than S&P 500 volatility due to the company’s 1.14 beta.

Liquidity

Ritter Pharmaceuticals Inc.’s Current Ratio is 5.1 while its Quick Ratio is 5.1. On the competitive side is, Opiant Pharmaceuticals Inc. which has a 7.9 Current Ratio and a 7.9 Quick Ratio. Opiant Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Ritter Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both Ritter Pharmaceuticals Inc. and Opiant Pharmaceuticals Inc. are owned by institutional investors at 24.3% and 20.3% respectively. 13.5% are Ritter Pharmaceuticals Inc.’s share held by insiders. Competitively, 0.2% are Opiant Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Ritter Pharmaceuticals Inc.	5.89%	10.35%	-16.1%	-68.84%	-73.95%	8.53%
Opiant Pharmaceuticals Inc.	6.24%	-2.82%	-1.69%	-29.26%	-26.8%	4.91%

For the past year Ritter Pharmaceuticals Inc. has stronger performance than Opiant Pharmaceuticals Inc.

Summary

Opiant Pharmaceuticals Inc. beats Ritter Pharmaceuticals Inc. on 5 of the 9 factors.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.